Actinium Pharmaceuticals, Inc.
ATNM
$1.26
$0.1614.55%
AMEX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -100.00% | -- | |||
| Total Revenue | -100.00% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -100.00% | -- | |||
| SG&A Expenses | 38.01% | -41.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.93% | -22.94% | |||
| Operating Income | -12.68% | 24.14% | |||
| Income Before Tax | -15.77% | 25.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.77% | 25.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.77% | 25.40% | |||
| EBIT | -12.68% | 24.14% | |||
| EBITDA | -16.08% | 24.84% | |||
| EPS Basic | -15.74% | 25.40% | |||
| Normalized Basic EPS | -15.76% | 25.40% | |||
| EPS Diluted | -15.74% | 25.40% | |||
| Normalized Diluted EPS | -15.76% | 25.40% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||